Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 122,159

Document Document Title
WO/2017/100062A1
Aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents. More particularly, aspects described herein relate to improved methods for infusing food and beverage composit...  
WO/2017/100599A1
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compou...  
WO/2017/099246A1
The present invention provides a transdermally absorbable preparation which is configured such that a medicine-containing adhesive layer is formed on a support material, wherein the adhesive layer contains at least a thermoplastic elasto...  
WO/2017/097728A1
The present invention relates to a compound of formula (I), wherein Het Ar is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted b...  
WO/2017/094838A1
By using a fluorescent ligand for a retinoid X receptor (RXR), said ligand being indicated by one of the following formulas (1)-(3), an evaluative test of ability to bind with RXR can be easily performed. (In the formulas, R1 is methyl, ...  
WO/2017/095734A1
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxymorphone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal...  
WO/2017/095214A1
The present invention relates to a solid, orally-administered veterinary pharmaceutical composition comprising: a) a drug selected from gabapentin and/or fluoxetine or a pharmaceutically acceptable salt of said drugs, preferably gabapent...  
WO/2017/095489A1
This invention generally relates to a composition and method for inducing the expansion and/or regeneration of CD34-positive adult stem cell population, which is useful for developing drugs/vaccines and/or therapies against a variety of ...  
WO/2017/093519A1
The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating an...  
WO/2017/093449A1
A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 1...  
WO/2017/096298A1
Provided herein are compounds that act as histone deacetylase (HDAC) inhibitors, and can affect expression of genes in vivo and in vitro. These HDAC inhibitors are generally volatile compounds that can be administered as a gas or vapor. ...  
WO/2017/095237A1
The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to prot...  
WO/2017/095458A1
This invention generally relates to a composition and method of using recombinant microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA) as therapeutic drugs for treating Alzheimer's diseases (AD). More specifically, the present...  
WO/2017/095904A1
Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin ...  
WO/2017/093718A1
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatingenzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin S...  
WO/2017/093897A1
Compositions comprising an antioxidant directed or indirectly conjugated to an aromatic-cationic peptide are provide. Said antioxidants are selected from TEMPO, Tro, PBN, AHDP, DBHP, Caf and Hem and may be conjugated to the aromatic-cati...  
WO/2017/093060A1
A medium-chain triglyceride (MCT) or medium-chain fatty acid (MCFA) for use in improving cognition which has been impaired by UBE3A deficiency.  
WO/2017/095759A1
In its many embodiments, the present invention provides certain C5-C6-carbocyclic fused iminothiazine dioxide compounds, including compounds Formula (I): and tautomers thereof, and pharmaceutically acceptable salts of said compounds and ...  
WO/2017/093363A1
The present invention is directed to a compound for use in the prevention or treatment of a neurodegenerative disease, in particular of a synucleinopathy. The present invention further is directed to a pharmaceutical composition containi...  
WO/2017/093807A1
The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive ...  
WO/2017/092638A1
The present invention relates to an opioid receptor antagonist derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to a naloxone derivative as shown by general formula (I) ...  
WO/2017/093890A1
The present invention relates to a pharmaceutical composition comprising clobazam or its pharmaceutically acceptable salt(s) or solvate(s) thereof of defined particle size and one or more pharmaceutically acceptable excipients.  
WO/2017/090716A1
The present invention provides type I crystals and type II crystals of 4-(2,5-dimethylpyrimidin-4-yl)-N-(6-fluoro-2-phenyl-[1,2,4]t riazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxami de that have an exceptional phosphodiesteras...  
WO/2017/088755A1
Disclosed hereinis an aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity, comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof. The aminopyrimidine heterocyclic ...  
WO/2017/088731A1
The present invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof, and pharmaceutical compositions containing these compounds. The compounds or the pharmaceutical compositions are used for antagonizing orexin re...  
WO/2017/088723A1
The present invention relates to a class of substituted triazolopiperazine compounds represented by general formula (I), tautomers, enantiomers, diastereomers, racemates, metabolites, metabolic precursors, and pharmaceutically acceptable...  
WO/2017/091661A1
The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to...  
WO/2017/088177A1
The present invention discloses a use of mussel adhesive proteins or a preparation thereof in preventing and suppressing a neuronal inflammation, and particularly discloses a use of mussel adhesive proteins or a preparation thereof in ne...  
WO/2017/089892A1
The present application relates to a compound of Formula (I), and to uses thereof, such the treatment of a neurological or psychoartic disorder.  
WO/2017/088759A1
The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also re...  
WO/2017/089458A1
The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as...  
WO/2017/091827A1
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxycodone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal u...  
WO/2017/089606A1
The present invention relates to a therapy for the treatment of demyelination, including multiple sclerosis, based upon suppressing the action of Ephrin-B1, Ephrin-B2 and Ephrin-B3. The demyelination may also be associated with other dis...  
WO/2017/088725A1
Disclosed are compounds as shown in General Formula (I), a preparation method therefor, and uses thereof. The compounds are weak in GPR17 antagonistic activity and strong in CysLT1 antagonism, can be used for preventing and treating cent...  
WO/2017/091719A1
The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.  
WO/2017/091592A1
The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and comp...  
WO/2017/091072A1
This invention relates to preparations comprising a butyrate salt for enteral administration for use in the treatment of conditions and diseases that are not diseases or conditions of the intestine and/or are associated with systemic inf...  
WO/2017/086835A1
The present invention relates to the chemical and pharmaceutical industries and medicine, and pertains to means for treating demyelinating diseases. A pharmaceutical composition in solid dosage form, exhibiting a therapeutic effect with ...  
WO/2017/085655A1
The present invention relates to compositions with a synergistic action between a mucoadherent gelling complex against the passage of antigens, and immunomodulatory anti-IL17 bacteria for use in the treatment of IL-17-related autoimmune ...  
WO/2017/087373A1
The invention relates to a modified release abuse deterrent tablet and a method for preparing the modified release abuse deterrent tablet.  
WO/2017/087594A1
Disclose are amine prodrugs and methods of synthesis thereof. In particular, the amine prodrug comprises a drug molecule and at least one or more prodrug appendage moieties and the method for synthesis the amine prodmg comprises a step o...  
WO/2017/085502A1
The present invention provides a transdermal delivery device comprising a pharmaceutical composition, wherein said composition comprises a N-oxide derivative of an opioid antagonist, or a salt thereof, and an opioid agonist or salt thereof.  
WO/2017/087445A1
The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).  
WO/2017/085035A1
The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs,...  
WO/2017/085198A1
The present invention relates to derivativesof formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pha...  
WO/2017/085350A1
The present invention relates to a combination comprising galanin and [Leu31,Pro34]NPY, and to the use of said combination for a disease of the nervous system, particularly depression. The invention also relates to a screening method for...  
WO/2017/085734A1
The present invention relates to crystalline forms of Tapentadol salts and process for preparation thereof. The structural formula of Tapentadol salts is represented as follows: [Formula should be inserted here].  
WO/2017/083983A1
The present disclosure generally relates to compounds comprising homotaurine that may be used in improving the general mental condition and/or general brain function of a non- human animal, and for the prophylaxis of chronic, aging-relat...  
WO/2017/087965A1
Processes and compositions for 2-heteroaryl substituted benzofuran derivatives are described. The 2-heteroaryl substituted benzofuran derivatives may be suitable for preparing radiolabeled 2-heteroaryl substituted benzofuran derivatives ...  
WO/2017/085362A1
The present invention is directed to a composition for intranasal administration comprising a CDNF polypeptide for use in the intranasal treatment of a central nervous system disease, such as Alzheimer's disease, Parkinson's disease, mul...  

Matches 51 - 100 out of 122,159